Highlights of brilaroxazine vocal or speech biomarker data from the pivotal Phase 3 RECOVER trial in schizophrenia include: Speech latencies classified the presence of moderate to severe negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback